Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial

被引:40
作者
Asher, Gary N. [1 ]
Viera, Anthony J. [1 ]
Weaver, Mark A. [2 ]
Dominik, Rosalie [3 ]
Caughey, Melissa [4 ]
Hinderliter, Alan L. [4 ]
机构
[1] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27514 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA
[4] Univ N Carolina, Div Cardiol, Chapel Hill, NC USA
来源
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2012年 / 12卷
关键词
Hawthorn; Crataegus; hypertension; prehypertension; flow mediated dilation; Phase I; ENDOTHELIUM-DEPENDENT VASODILATION; CRATAEGUS; AGE; VASORELAXATION; ASSOCIATION; RELAXATION; TINCTURE; NITRITE; ARTERY;
D O I
10.1186/1472-6882-12-26
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Hawthorn extract has been used for cardiovascular diseases for centuries. Recent trials have demonstrated its efficacy for the treatment of heart failure, and the results of several small trials suggest it may lower blood pressure. However, there is little published evidence to guide its dosing. The blood pressure lowering effect of hawthorn has been linked to nitric oxide-mediated vasodilation. The aim of this study was to investigate the relationship between hawthorn extract dose and brachial artery flow mediated dilation (FMD), an indirect measure of nitric oxide release. Methods: We used a four-period cross-over design to evaluate brachial artery FMD in response to placebo or hawthorn extract (standardized to 50 mg oligomeric procyanidin per 250 mg extract). Randomly sequenced doses of hawthorn extract (1000 mg, 1500 mg, and 2500 mg) and placebo were assigned to each participant. Doses were taken twice daily for 3 1/2 days followed by FMD and a 4-day washout before proceeding to the next dosing period. Results: Twenty-one prehypertensive or mildly hypertensive adults completed the study. There was no evidence of a dose-response effect for our main outcome (FMD percent) or any of our secondary outcomes (absolute change in brachial artery diameter and blood pressure). Most participants indicated that if given evidence that hawthorn could lower their blood pressure, they would be likely to use it either in conjunction with or instead of lifestyle modification or anti-hypertensive medications. Conclusion: We found no evidence of a dose-response effect of hawthorn extract on FMD. If hawthorn has a blood pressure lowering effect, it is likely to be mediated via an NO-independent mechanism.
引用
收藏
页数:7
相关论文
共 37 条
[21]  
Pickering Thomas G., 2005, Hypertension (Baltimore), V45, P142
[22]   Hawthorn extract for treating chronic heart failure [J].
Pittler, M. H. ;
Guo, R. ;
Emst, E. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01)
[23]   Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet [J].
Rajendran, S ;
Deepalakshmi, PD ;
Parasakthy, K ;
Devaraj, H ;
Devaraj, SN .
ATHEROSCLEROSIS, 1996, 123 (1-2) :235-241
[24]   L-arginine therapy in acute myocardial infarction - The Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial [J].
Schulman, SP ;
Becker, LC ;
Kass, DA ;
Champion, HC ;
Terrin, ML ;
Forman, S ;
Ernst, KV ;
Kelemen, MD ;
Townsend, SN ;
Capriotti, A ;
Hare, JM ;
Gerstenblith, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :58-64
[25]  
Shanthi R, 1996, J CLIN BIOCHEM NUTR, V20, P211
[26]  
SHANTHI S, 1994, INDIAN J BIOCHEM BIO, V31, P143
[27]   The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort [J].
Shimbo, Daichi ;
Grahame-Clarke, Cairistine ;
Miyake, Yumiko ;
Rodriguez, Carlos ;
Sciacca, Robert ;
Di Tullio, Marco ;
Boden-Albala, Bernadette ;
Sacco, Ralph ;
Homma, Shunichi .
ATHEROSCLEROSIS, 2007, 192 (01) :197-203
[28]   Age-related reduction of NO availability and oxidative stress in humans [J].
Taddei, S ;
Virdis, A ;
Ghiadoni, L ;
Salvetti, G ;
Bernini, G ;
Magagna, A ;
Salvetti, A .
HYPERTENSION, 2001, 38 (02) :274-279
[29]   Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure [J].
Tauchert, M .
AMERICAN HEART JOURNAL, 2002, 143 (05) :910-915
[30]  
Tauchert R, 1999, HERZ, V24, P465